Nishioka, C., Tahata, Y., Maesaka, K., Kai, M., Shirai, K., Murai, K., Makino, Y., Saito, Y., Nozaki, Y., Nakabori, T., Ishida, H., Yakushijin, T., Iio, S., Tatsumi, N., Imanaka, K., Kakita, N., Sakamori, R., Hosui, A., Miyazaki, M., Matsumoto, K., Nakahara, M., Doi, Y., Sakakibara, M., Hikita, H., Kodama, T., Takehara, T. (2026). Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. PLoS ONE. https://doi.org/10.1371/journal.pone.0341395